Effect of chronic administration of nicorandil (a potassium channel activator) on body weight of two different experimental animal species





Body weight, Chronic administration, Graded dose, Nicorandil, Potassium channel activator


Background: Potassium channel openers (Nicorandil being the prototype) are a distinct class of drugs, used in the management of chronic stable angina pectoris. Obesity is a frequent co-morbid condition and also a risk factor for angina pectoris. Anti-obesity drugs are used more frequently these days than ever before. Therefore, it is more likely that physician would be prescribing at least 2 or more drugs while treating such comorbid conditions. This generates a need for the development of a new drug which would work against both angina and obesity. The resultant effect would be a reduction in the cost burden, incidences of side effects and possible drug- drug interactions as compared to multidrug therapy. The purpose of this study is evaluating the chronic effect of Nicorandil (graded doses) on the body weight in 2 different species of animals i.e. rabbits and mice.

Methods: In this study, 30 experimental animals of each species were selected. Pretreatment weight (Mean body weight±SEM) of each group were recorded and compared with the post-treatment values of the respective group in every week up to a period of 4 weeks. The route of administration was an intraperitoneal injection.

Results: Chronic administration of nicorandil causes a significant reduction in body weight at moderate to high doses in both species of the study group. (p <0.05).

Conclusions: Body weight reducing, an effect of nicorandil in animals, if established in human, could enhance its acceptability in obesity with various ischemic heart diseases including angina.


Ford I. Impact of nicorandil in angina: subgroup analyses. Heart 2004;90(12):1427-30.

Aizawa T, Ogasawara K, Kato K. Effects of Nicorandil on Coronary Circulation in Patients with Ischemic Heart Disease. Journal of Cardiovascular Pharmacology. 1987;10:123-9.

Frampton J, Buckley M, Fitton A. Nicorandil. Drugs 1992;44(4):625-55.

Purcell H, Fox K. Potassium channel openers in myocardial ischemia – clinical experience with nicorandil. Journal of Clinical and Basic Cardiology. 1999;2(1):12-4.

Essentials of Medical Pharmacology. 5th Ed. Delhi, India: Jaypee; 2004:498.

Kukovetz W, Holzmann S, Pöch G. Molecular Mechanism of Action of Nicorandil. Journal of Cardiovascular Pharmacology. 1992;20:1-7.

Kinoshita, M, Sakai, K. Pharmacology and therapeutic effects of nicorandil. Cardiovascular Drugs and Therapy. 1990;4(4):1075-88.

Mayo Clinic. Angina Risk factors: Angina, 2017. Available at: http://www.mayoclinic.org/diseases-conditions/angina/basics/risk-factors/con-20031194. Accessed 25 Apr. 2017.

Lai, S, Nq K, Lin H, Chen H. Association between obesity and hyperlipidemia among children. Yale J Biol Med. 2001;74(4):205-10.

Gostynski M, Gutzwiller F, Kuulasmaa K, Döring A, Ferrario M, Grafnetter D, et al. Analysis of the relationship between total cholesterol, age, body mass index among males and females in the WHO MONICA Project. International Journal of Obesity. 2004;28(8):1082-90.

Golomb B, Statin EM. Adverse Effects. American Journal of Cardiovascular Drugs. 2008;8(6):373-418.

Mayo Clinic. Obesity Treatments and drugs, 2017. Available at: http://www.mayoclinic.org/diseases-conditions/obesity/basics/treatment/con-20014834. Accessed 25 Apr. 2017.

Stafford R, Radley D. National Trends in Antiobesity Medication Use. Archives of Internal Medicine. 2003;163(9):1046.

Zuo X, Wang Q, Cao Q, Yu Y, Wang H, Bi L, et al. Nicorandil Prevents Right Ventricular Remodeling by Inhibiting Apoptosis and Lowering Pressure Overload in Rats with Pulmonary Arterial Hypertension. PLoS ONE. 2012;7(9):44485.

Diehl K, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, et al. A good practice guide to the administration of substances and removal of blood including routes and volumes. Journal of Applied Toxicology. 2001;21(1):15-23.

Krumenacker M, Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol. 1992;20(3):93-102.

Greenway F. Physiological adaptations to weight loss and factors favouring weight regain. International Journal of Obesity. 2015;39(8):1188-96.

Aguilar-Nascimento, J. Fundamental steps in experimental design for animal studies. Acta Cirurgica Brasileira. 2005;20(1).




How to Cite

Das, S., Alsalhanie, K. M., Nauhria, S., & Datta, A. N. (2017). Effect of chronic administration of nicorandil (a potassium channel activator) on body weight of two different experimental animal species. International Journal of Basic & Clinical Pharmacology, 6(7), 1567–1571. https://doi.org/10.18203/2319-2003.ijbcp20172717



Original Research Articles